These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 32150281)
1. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. Luebke AM; Ricken W; Kluth M; Hube-Magg C; Schroeder C; Büscheck F; Möller K; Dum D; Höflmayer D; Weidemann S; Fraune C; Hinsch A; Wittmer C; Schlomm T; Huland H; Heinzer H; Graefen M; Haese A; Minner S; Simon R; Sauter G; Wilczak W; Meiners J Int J Cancer; 2020 Jul; 147(2):575-583. PubMed ID: 32150281 [TBL] [Abstract][Full Text] [Related]
2. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408 [TBL] [Abstract][Full Text] [Related]
3. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965 [TBL] [Abstract][Full Text] [Related]
4. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228 [TBL] [Abstract][Full Text] [Related]
5. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607 [TBL] [Abstract][Full Text] [Related]
6. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. Fraune C; Harms L; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Möller K; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Sauter G; Weidemann S; Lebok P; Dum D; Kind S; Minner S; Izbicki JR; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Schroeder C Mol Med; 2020 Mar; 26(1):24. PubMed ID: 32143573 [TBL] [Abstract][Full Text] [Related]
7. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028 [TBL] [Abstract][Full Text] [Related]
9. Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. Minner S; Hager D; Steurer S; Höflmayer D; Tsourlakis MC; Möller-Koop C; Clauditz TS; Hube-Magg C; Luebke AM; Simon R; Sauter G; Göbel C; Weidemann S; Lebok P; Dum D; Fraune C; Izbicki J; Burandt E; Schlomm T; Huland H; Heinzer H; Haese A; Graefen M; Heumann A Neoplasia; 2019 Sep; 21(9):872-881. PubMed ID: 31382165 [TBL] [Abstract][Full Text] [Related]
10. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739 [TBL] [Abstract][Full Text] [Related]
12. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301 [TBL] [Abstract][Full Text] [Related]
13. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067 [TBL] [Abstract][Full Text] [Related]
14. Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. Höflmayer D; Steinhoff A; Hube-Magg C; Kluth M; Simon R; Burandt E; Tsourlakis MC; Minner S; Sauter G; Büscheck F; Wilczak W; Steurer S; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Jacobsen F; Hinsch A; Poos AM; Oswald M; Rippe K; König R; Schroeder C Mol Oncol; 2020 Jan; 14(1):129-138. PubMed ID: 31736271 [TBL] [Abstract][Full Text] [Related]
15. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277 [TBL] [Abstract][Full Text] [Related]
16. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051 [TBL] [Abstract][Full Text] [Related]
17. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. Kind S; Kluth M; Hube-Magg C; Möller K; Makrypidi-Fraune G; Lutz F; Lennartz M; Rico SD; Schlomm T; Heinzer H; Höflmayer D; Weidemann S; Uhlig R; Huland H; Graefen M; Bernreuther C; Tsourlakis MC; Minner S; Dum D; Hinsch A; Lübke AM; Simon R; Sauter G; Marx A; Polonski A Biomed Res Int; 2020; 2020():5845374. PubMed ID: 33195694 [TBL] [Abstract][Full Text] [Related]
18. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445 [TBL] [Abstract][Full Text] [Related]
19. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842 [TBL] [Abstract][Full Text] [Related]
20. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]